AT

AptarGroup, Inc.

ATRHealthcareNASDAQ

Medical Instruments & Supplies · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.78B
+5.4% YoY
Net Income
$392.8M
+4.9% YoY
EBITDA
$831.5M
+6.9% YoY
Free Cash Flow
$266.0M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Aug 12 MACD Negative CrossoverHistogram -0.3441, negative momentum
Aug 11 MACD Negative CrossoverHistogram -0.2577, negative momentum
About AptarGroup, Inc.

Part of the healthcare sector, AptarGroup, Inc. (ATR) is listed under Medical Instruments & Supplies. The $8.10B market capitalization puts ATR squarely in mid-cap range for its industry. The company operates through three segments: Pharma, Beauty, and Closures.

Where ATR stands vs its 150-day and 200-day moving averages

As of the August 12, 2026 close, ATR finished 6.84% above its 150-day moving average ($126.12) and 8.20% above its 200-day moving average ($124.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is ATR overbought or oversold?

At the August 12, 2026 close, ATR's RSI(14) was 64.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$8.10B
P/E (TTM)23.00
Fwd P/E20.17
EPS$5.54
Beta0.38
52W Change-7.0%
Dividend Yield1.51%
ROE13.5%
Analysis

AptarGroup, Inc. carries $1.41B in total debt against $197.3M in cash reserves — debt is roughly 7.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $266.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 13.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $3.32B to $3.78B.

With a beta below 0.7, AptarGroup, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AptarGroup, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms